2022.11.03
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.
2022.10.05
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
I-Mab will present new preclinical data of its core assets lemzoparlimab and uliledlimab at the 37th SITC Annual Meeting.
2022.09.13
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
2022.09.10
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
I-Mab today announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed HR-MDS.
2022.09.06
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
I-Mab today announced that the results from its Phase 2 clinical study of lemzoparlimab in combination with azacitidine in patients with HR-MDS will be featured in a proffered paper presentation at the upcoming ESMO Congress 2022.
2022.08.30
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
I-Mab today announced financial results for the six months ended June 30, 2022, and provided key business updates.
2022.08.23
I-Mab Announces Share Purchase Plans by the Company and the Senior Management
I-Mab today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.
2022.08.19
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
I-Mab will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022.
2022.07.22
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
I-Mab today announced that the first patient in China has been treated with TJ-CD4B in a Phase 1 IMCT for patients with solid tumors.
2022.07.18
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
I-Mab today announced that it will present the latest Phase 2 clinical data of lemzoparlimab in combination with azacitidine in patients with higher risk myelodysplastic syndrome as a proffered paper at 2022 ESMO Congress.